Clinical Research Directory
Browse clinical research sites, groups, and studies.
CYTALUX™for the Intraoperative Imaging of Prostate Cancer
Sponsor: Indiana University
Summary
This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in ovarian cancer (2021) and lung cancer surgery (2022.)
Official title: An Investigator Sponsored Study to Investigate the Safety and Efficacy of CYTALUX™ (PAFOLACIANINE) INJECTION for the Intraoperative Imaging of Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
9
Start Date
2024-09-19
Completion Date
2025-09-04
Last Updated
2026-06-01
Healthy Volunteers
No
Conditions
Interventions
Cytalux™ (pafolacianine) for fluorescent imaging
Cytalux™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye for real-time cancer margin status. This is used in conjunction with appropriate imaging system.
Image Guided Surgery
prostatectomy using appropriate imaging system
Locations (3)
IU Health Joe and Shelly Schwarz Cancer Center
Carmel, Indiana, United States
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Indiana University Health Methodist Hospital
Indianapolis, Indiana, United States